Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 5,290

Document Document Title
WO/2011/016648A1
Provided are novel organic electroluminescent compounds and an organic electroluminescent device using the same. Since the organic electroluminescent compound disclosed herein exhibits good luminescent efficiency and excellent life prope...  
WO/2011/012810A1
The invention relates to 2-amino-2-phenyl-alkanol-derived esters of general formula (I), where: R1 forms, with R3 and the nitrogen and carbon atoms to which they are respectively attached, a 4- to 7-membered heterocyclic compound, option...  
WO/2010/113179A3
A process for purifying eslicarbazepine acetate is provided The crystalline particles of eslicarbazepine acetate having a median particle size between 5 μm and 20 μm and a specific surface area of from 0.1 m2/g to 10 m2/g as measured b...  
WO/2009/139001A3
The present invention relates to an improved process for the preparation of 10-oxo- 10,l l-dihydiO-5H-dibenz[b,fjazepine-5-carboxamide (Oxcarbazepine) by reacting 10-methoxy-5H-dibenz[b,f]azepine (10-methoxyiminostilbene) and alkali meta...  
WO/2011/010843A1
The present invention relates to organic electroluminescent compounds and an organic electroluminescent device using the same. The organic electroluminescent compound accordingly to the present invention is represented by Chemical Formul...  
WO/2011/007247A1
Carbamate linked prodrugs of meptazinol and other opioid analgesics are provided. The prodrug moiety may comprise a single amino acid or short peptide. Additionally, the present invention relates to methods for reducing gastrointestinal ...  
WO/2010/096384A3
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and t...  
WO/2011/000915A1
The present invention relates to compounds of formula (I) as isoform-selective HCN blockers. In particular said compounds showed diverse capabilities of blocking selectively isoforms HCN1, HCN2 and HCN4 expressed in HEK cells. The invent...  
WO/2010/129057A3
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical compositi...  
WO/2010/151006A1
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound disclosed herein exhibits good luminescence efficiency and excellent life pro...  
WO/2010/144873A1
The present invention generally relates to processes for the chemocatalytic conversion of a carbohydrate source to an adipic acid product. The present invention includes processes for the conversion of a carbohydrate source to an adipic ...  
WO/2010/144862A2
The present invention generally relates to processes for the chemocatalytic conversion of a glucose source to an adipic acid product. The present invention includes processes for the conversion of glucose to an adipic acid product via gl...  
WO/2010/125040A1
The present invention relates to a method for preparing lactams by cyclising hydrolysis of a corresponding aminonitrile. The invention relates to a method for manufacturing a lactam by reacting an aminonitrile with water in the presence ...  
WO/2010/123139A1
Disclosed is a long-chain fatty acid elongase (Elovl6) inhibitor, which is characterized by comprising at least one of a compound represented by formula (I), a pharmaceutically acceptable salt of the compound, and a solvate of the compou...  
WO/2010/122134A1
The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).  
WO/2010/119274A1
A monomer having the general formula (a): in which R1 is any substitution; R2 is any substitution; R1 and R2 may be linked to form a saturated or unsaturated ring; L represents a reactive leaving group; X and Y each independently represe...  
WO/2010/112705A1
The invention relates to a method for the synthesis of ivabradine having formula (I) and the addition salts thereof with a pharmaceutically acceptable acid.  
WO/2010/112704A1
The invention relates to a method for the synthesis of ivabradine having formula (I) and the addition salts thereof with a pharmaceutically acceptable acid.  
WO/2010/113179A2
The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions co...  
WO/2010/112942A1
The present invention concerns dicarboxylic acid linked amino acid and peptide prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, decreasing the adverse GI side effe...  
WO/2010/111116A1
A molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-lH- azepin-l-yl)-l,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction ("XRPD") spectrum that comprises peak...  
WO/2010/096384A2
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and t...  
WO/2010/089475A1
The invention relates to a method for the synthesis of ivabradine having formula (I) and the pharmaceutically acceptable acid addition salts thereof.  
WO/2010/081342A1
Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods ther...  
WO/2010/041943A3
The invention relates to a method for preparing ε-caprolactam comprising deacylating N-acyl-6-aminocaproic acid and forming ε-caprolactam. The deacylation may be carried out chemically or biocatalytically. The invention further relates...  
WO/2010/079324A1
A redox ammoximation process in which a ketone or aldehyde is reacted with ammonia and oxygen in the presence of a catalyst, wherein: the catalyst is an aluminophosphate based redox catalyst having the qualitative general formula (I) M1M...  
WO/2010/072409A1
The present invention describes a new process for optical resolution of [N-[[3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methy lamine] which is an intermediate in the preparation of ivabradine.  
WO/2010/011924A3
The invention relates to monomers that are derived from α- and β-amino-ε-caprolactam and to polymers (e.g., homopolymers and copolymers) prepared from these monomers. In many embodiments, the α-amino-ε-caprolactam or β-amino-ε-cap...  
WO/2010/072930A1
The invention relates to a method for the synthesis of ivabradine of formula (I) and of the salts thereof for addition to a pharmaceutically acceptable acid.  
WO/2010/064871A1
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells including the same. The organic electroluminescent compound provides superior luminous efficiency and excellent color...  
WO/2010/062107A1
Provided is an electroluminescent device including an organic layer interposed between an anode and a cathode on a substrate, wherein the organic layer includes an electroluminescent layer containing one or more dopant compound(s) of for...  
WO/2010/054215A1
The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some ...  
WO/2010/050779A1
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. The organic electroluminescent compounds according to the present invention exhibit high luminou...  
WO/2009/153461A3
Method for the synthesis of the compound of formula (I). Use in the synthesis of ivabradine, of addition salts thereof with a pharmaceutically acceptable acid, and of hydrates thereof.  
WO/2010/048017A1
The present invention is directed to disubstituted azepan and oxazepan amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases ...  
WO/2010/042998A1
The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pha...  
WO/2010/041943A2
The invention relates to a method for preparing ε-caprolactam comprising deacylating N-acyl-6-aminocaproic acid and forming ε-caprolactam. The deacylation may be carried out chemically or biocatalytically. The invention further relates...  
WO/2010/037257A1
New benzazepine compounds, preparation methods and uses thereof, especially, new benzazepine compounds of following formula (I) or stereoisomers, pharmaceutically acceptable salts or pharmaceutically acceptable hydrates thereof, and the ...  
WO/2010/031719A1
The invention relates to a method for the continuous production of an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group comprising ammonia, and primary...  
WO/2010/007382A8
A compound having the formula (1) wherein: R1 is a group selected from C3-8 cycloalkyl, C1-6 alkyl, C1-6 alkylene-C3-8 cycloalkyl, each of which groups may optionally be substituted with C1-6 alkyl, halogen, haloC1-6 alkyl or OR15, or R1...  
WO/2010/026989A1
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by general formula (1) [wherein A represents –C(R7)(R8)- or –N(R9)-; W represents an oxygen atom or a sulfur atom; n represents...  
WO/2008/146308A3
The present invention encompasses a process for the preparation of highly pure ivabradine hydrochloride by treating ivabradine with alcoholic hydrogen chloride. The invention further encompasses amorphous ivabradine hydrochloride and pro...  
WO/2010/023383A1
Method for optical resolution of the compound of formula (I): by chiral chromatography. Use in the synthesis of ivabradine, of addition salts thereof with a pharmaceutically acceptable acid and of hydrates thereof.  
WO/2010/021149A1
Disclosed is a novel prophylactic/therapeutic agent for digestive system diseases. The prophylactic/therapeutic agent for digestive system diseases comprises a compound represented by the formula or a salt or prodrug thereof. In the form...  
WO/2009/092073A3
The present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid analgesic. The methods comprise orally administerin...  
WO/2009/092071A3
Prodrugs of meptazinol and other phenolic analgesics exhibiting low oral bioavailability with amino acids or lower peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with such prodrugs a...  
WO/2010/012812A1
The present invention relates to derivatives of benzoannulated nitrogen heterocycles, methods for the production thereof, the use thereof as medication, and medication containing derivatives of benzoannulated nitrogen heterocycles.  
WO/2010/011967A1
The present invention relates to methods of making a cyclic amide. The methods include the step of heating a fermentation broth in a manner effective to produce a cyclic amide (e.g., α-amino-ε-caprolactam), wherein the fermentation bro...  
WO/2010/011924A2
The invention relates to monomers that are derived from α- and β-amino-ε-caprolactam and to polymers (e.g., homopolymers and copolymers) prepared from these monomers. In many embodiments, the α-amino-ε-caprolactam or β-amino-ε-cap...  
WO/2010/007027A1
The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13....  

Matches 351 - 400 out of 5,290